NASDAQ:CALT

Calliditas Therapeutics AB (publ) Competitors

$26.98
+0.96 (+3.69 %)
(As of 04/21/2021 11:21 AM ET)
Add
Compare
Today's Range
$26.98
Now: $26.98
$26.98
50-Day Range
$26.72
MA: $28.27
$30.03
52-Week Range
$19.00
Now: $26.98
$38.00
Volume40 shs
Average Volume32,116 shs
Market Capitalization$673.72 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Vs. FOLD, GBT, ITCI, LGND, XNCR, and DRNA

Should you be buying CALT stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Calliditas Therapeutics AB (publ), including Amicus Therapeutics (FOLD), Global Blood Therapeutics (GBT), Intra-Cellular Therapies (ITCI), Ligand Pharmaceuticals (LGND), Xencor (XNCR), and Dicerna Pharmaceuticals (DRNA).

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Amicus Therapeutics (NASDAQ:FOLD) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, valuation, risk and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Calliditas Therapeutics AB (publ) and Amicus Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Calliditas Therapeutics AB (publ)00503.00
Amicus Therapeutics07602.46

Calliditas Therapeutics AB (publ) currently has a consensus target price of $40.80, indicating a potential upside of 51.22%. Amicus Therapeutics has a consensus target price of $20.0385, indicating a potential upside of 104.89%. Given Amicus Therapeutics' higher probable upside, analysts plainly believe Amicus Therapeutics is more favorable than Calliditas Therapeutics AB (publ).

Institutional & Insider Ownership

11.9% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 2.5% of Amicus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Calliditas Therapeutics AB (publ) and Amicus Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calliditas Therapeutics AB (publ)$19.56 million34.44$-3,450,000.00($0.19)-142.00
Amicus Therapeutics$182.24 million14.20$-356,390,000.00($1.31)-7.47

Calliditas Therapeutics AB (publ) has higher earnings, but lower revenue than Amicus Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Amicus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Calliditas Therapeutics AB (publ) and Amicus Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Calliditas Therapeutics AB (publ)N/A-26.80%-25.38%
Amicus Therapeutics-120.18%-73.81%-36.10%

Summary

Calliditas Therapeutics AB (publ) beats Amicus Therapeutics on 8 of the 13 factors compared between the two stocks.

Global Blood Therapeutics (NASDAQ:GBT) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Global Blood Therapeutics and Calliditas Therapeutics AB (publ), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Global Blood Therapeutics051402.74
Calliditas Therapeutics AB (publ)00503.00

Global Blood Therapeutics presently has a consensus price target of $90.3158, indicating a potential upside of 116.38%. Calliditas Therapeutics AB (publ) has a consensus price target of $40.80, indicating a potential upside of 51.22%. Given Global Blood Therapeutics' higher probable upside, equities research analysts clearly believe Global Blood Therapeutics is more favorable than Calliditas Therapeutics AB (publ).

Institutional & Insider Ownership

11.9% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 4.3% of Global Blood Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Global Blood Therapeutics and Calliditas Therapeutics AB (publ)'s revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Global Blood Therapeutics$2.11 million1,225.76$-266,770,000.00($4.71)-8.83
Calliditas Therapeutics AB (publ)$19.56 million34.44$-3,450,000.00($0.19)-142.00

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Global Blood Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Global Blood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Global Blood Therapeutics and Calliditas Therapeutics AB (publ)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Global Blood Therapeutics-332.94%-56.43%-39.32%
Calliditas Therapeutics AB (publ)N/A-26.80%-25.38%

Summary

Calliditas Therapeutics AB (publ) beats Global Blood Therapeutics on 8 of the 13 factors compared between the two stocks.

Intra-Cellular Therapies (NASDAQ:ITCI) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Intra-Cellular Therapies and Calliditas Therapeutics AB (publ), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intra-Cellular Therapies00703.00
Calliditas Therapeutics AB (publ)00503.00

Intra-Cellular Therapies presently has a consensus price target of $47.4286, indicating a potential upside of 61.16%. Calliditas Therapeutics AB (publ) has a consensus price target of $40.80, indicating a potential upside of 51.22%. Given Intra-Cellular Therapies' higher probable upside, equities research analysts clearly believe Intra-Cellular Therapies is more favorable than Calliditas Therapeutics AB (publ).

Institutional & Insider Ownership

79.1% of Intra-Cellular Therapies shares are held by institutional investors. Comparatively, 11.9% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 18.2% of Intra-Cellular Therapies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Intra-Cellular Therapies and Calliditas Therapeutics AB (publ)'s revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intra-Cellular Therapies$60,000.0039,878.59$-147,720,000.00($2.68)-11.03
Calliditas Therapeutics AB (publ)$19.56 million34.44$-3,450,000.00($0.19)-142.00

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Intra-Cellular Therapies. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Intra-Cellular Therapies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Intra-Cellular Therapies and Calliditas Therapeutics AB (publ)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intra-Cellular Therapies-1,985.32%-48.27%-42.56%
Calliditas Therapeutics AB (publ)N/A-26.80%-25.38%

Ligand Pharmaceuticals (NASDAQ:LGND) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Ligand Pharmaceuticals and Calliditas Therapeutics AB (publ), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ligand Pharmaceuticals01602.86
Calliditas Therapeutics AB (publ)00503.00

Ligand Pharmaceuticals presently has a consensus price target of $215.60, indicating a potential upside of 45.18%. Calliditas Therapeutics AB (publ) has a consensus price target of $40.80, indicating a potential upside of 51.22%. Given Calliditas Therapeutics AB (publ)'s stronger consensus rating and higher probable upside, analysts clearly believe Calliditas Therapeutics AB (publ) is more favorable than Ligand Pharmaceuticals.

Institutional & Insider Ownership

11.9% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 10.6% of Ligand Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Ligand Pharmaceuticals and Calliditas Therapeutics AB (publ)'s revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ligand Pharmaceuticals$120.28 million20.46$629.30 million$2.1170.19
Calliditas Therapeutics AB (publ)$19.56 million34.44$-3,450,000.00($0.19)-142.00

Ligand Pharmaceuticals has higher revenue and earnings than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ligand Pharmaceuticals and Calliditas Therapeutics AB (publ)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ligand Pharmaceuticals-11.23%5.90%3.22%
Calliditas Therapeutics AB (publ)N/A-26.80%-25.38%

Summary

Ligand Pharmaceuticals beats Calliditas Therapeutics AB (publ) on 7 of the 13 factors compared between the two stocks.

Xencor (NASDAQ:XNCR) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Xencor and Calliditas Therapeutics AB (publ), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Xencor20702.56
Calliditas Therapeutics AB (publ)00503.00

Xencor presently has a consensus price target of $47.1111, indicating a potential upside of 12.81%. Calliditas Therapeutics AB (publ) has a consensus price target of $40.80, indicating a potential upside of 51.22%. Given Calliditas Therapeutics AB (publ)'s stronger consensus rating and higher probable upside, analysts clearly believe Calliditas Therapeutics AB (publ) is more favorable than Xencor.

Institutional & Insider Ownership

11.9% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 3.7% of Xencor shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Xencor and Calliditas Therapeutics AB (publ)'s revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xencor$156.70 million15.38$26.88 million$0.4690.43
Calliditas Therapeutics AB (publ)$19.56 million34.44$-3,450,000.00($0.19)-142.00

Xencor has higher revenue and earnings than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Xencor and Calliditas Therapeutics AB (publ)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Xencor-113.40%-13.56%-12.03%
Calliditas Therapeutics AB (publ)N/A-26.80%-25.38%

Summary

Xencor beats Calliditas Therapeutics AB (publ) on 7 of the 13 factors compared between the two stocks.

Dicerna Pharmaceuticals (NASDAQ:DRNA) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

Profitability

This table compares Dicerna Pharmaceuticals and Calliditas Therapeutics AB (publ)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dicerna Pharmaceuticals-88.81%-71.72%-16.60%
Calliditas Therapeutics AB (publ)N/A-26.80%-25.38%

Valuation & Earnings

This table compares Dicerna Pharmaceuticals and Calliditas Therapeutics AB (publ)'s revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dicerna Pharmaceuticals$23.90 million93.02$-120,460,000.00($1.76)-16.55
Calliditas Therapeutics AB (publ)$19.56 million34.44$-3,450,000.00($0.19)-142.00

Calliditas Therapeutics AB (publ) has lower revenue, but higher earnings than Dicerna Pharmaceuticals. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Dicerna Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Dicerna Pharmaceuticals and Calliditas Therapeutics AB (publ), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dicerna Pharmaceuticals00703.00
Calliditas Therapeutics AB (publ)00503.00

Dicerna Pharmaceuticals presently has a consensus price target of $40.4444, indicating a potential upside of 38.51%. Calliditas Therapeutics AB (publ) has a consensus price target of $40.80, indicating a potential upside of 51.22%. Given Calliditas Therapeutics AB (publ)'s higher probable upside, analysts clearly believe Calliditas Therapeutics AB (publ) is more favorable than Dicerna Pharmaceuticals.

Institutional & Insider Ownership

80.6% of Dicerna Pharmaceuticals shares are held by institutional investors. Comparatively, 11.9% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 11.3% of Dicerna Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Dicerna Pharmaceuticals beats Calliditas Therapeutics AB (publ) on 7 of the 12 factors compared between the two stocks.


Calliditas Therapeutics AB (publ) Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.79+0.1%$2.59 billion$182.24 million-8.51Analyst Upgrade
Insider Selling
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$41.61+0.8%$2.57 billion$2.11 million-9.01Analyst Report
News Coverage
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$29.57+3.3%$2.47 billion$60,000.00-9.18Analyst Revision
News Coverage
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$148.11+0.9%$2.44 billion$120.28 million-149.61Decrease in Short Interest
Xencor logo
XNCR
Xencor
1.2$41.60+0.1%$2.41 billion$156.70 million-29.71
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
2.0$29.13+4.6%$2.32 billion$23.90 million-18.09Analyst Report
Insider Selling
Analyst Revision
News Coverage
Arcus Biosciences logo
RCUS
Arcus Biosciences
1.8$33.09+3.4%$2.26 billion$15 million-17.32
Cryoport logo
CYRX
Cryoport
1.7$51.58+3.8%$2.26 billion$33.94 million-88.93
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$45.54+0.8%$2.25 billion$963.01 million14.14
ALX Oncology logo
ALXO
ALX Oncology
1.9$56.87+4.3%$2.18 billionN/A0.00
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.4$53.72+4.7%$2.10 billionN/A0.00Analyst Report
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$129.10+2.1%$2.02 billionN/A-11.66News Coverage
MacroGenics logo
MGNX
MacroGenics
1.2$33.57+0.3%$2.02 billion$64.19 million-10.73Analyst Report
Insider Selling
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$26.58+3.0%$1.98 billion$103.54 million-19.98
Amarin logo
AMRN
Amarin
1.6$5.08+2.6%$1.95 billion$429.76 million-101.58
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.39+2.2%$1.91 billion$410,000.00-5.95
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$51.04+0.8%$1.89 billionN/A-18.97Unusual Options Activity
News Coverage
FibroGen logo
FGEN
FibroGen
1.8$20.33+0.1%$1.87 billion$256.58 million-7.79
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$58.04+0.1%$1.86 billionN/A-24.70
Kura Oncology logo
KURA
Kura Oncology
1.6$27.80+0.5%$1.85 billionN/A-17.06News Coverage
Cytokinetics logo
CYTK
Cytokinetics
1.7$25.17+0.5%$1.81 billion$26.87 million-13.18Analyst Report
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$19.86+1.3%$1.79 billion$34.51 million-16.97
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05+0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$38.00+0.0%$1.77 billion$14.87 million-14.18
MORF
Morphic
1.3$56.80+4.5%$1.76 billion$16.98 million-36.41Gap Up
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.74+0.7%$1.72 billion$428.41 million15.57Analyst Upgrade
Unusual Options Activity
News Coverage
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.8$5.68+0.2%$1.70 billion$1.63 billion13.85
Generation Bio logo
GBIO
Generation Bio
1.8$30.16+0.2%$1.70 billionN/A0.00Gap Up
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$17.70+0.5%$1.63 billion$145.97 million-7.17
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.7$31.35+2.1%$1.62 billion$392.76 million13.01Analyst Upgrade
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$18.91+5.6%$1.62 billionN/A-6.73Analyst Downgrade
Increase in Short Interest
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$23.26+1.2%$1.58 billion$2.34 million-9.86
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$27.68+0.9%$1.56 billionN/A0.00
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.5$34.97+5.0%$1.55 billionN/A0.00Analyst Upgrade
News Coverage
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$25.70+1.9%$1.52 billion$175.34 million-15.12Insider Selling
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.06+1.6%$1.51 billion$320,000.00-8.20
uniQure logo
QURE
uniQure
1.7$31.83+2.1%$1.46 billion$7.28 million-8.44Unusual Options Activity
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.45+1.7%$1.46 billion$82.27 million-18.17
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$29.48+2.8%$1.44 billionN/A-3.19Analyst Upgrade
Gap Up
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$61.95+1.1%$1.43 billionN/A0.00
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$22.17+0.4%$1.42 billion$73.41 million-4.69News Coverage
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$40.15+1.0%$1.40 billionN/A0.00
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$32.01+2.3%$1.40 billionN/A0.00Gap Down
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$31.89+0.5%$1.38 billion$6.20 million-13.99
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$27.77+1.0%$1.37 billion$19.89 million-13.10
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$27.73+4.6%$1.37 billion$4.23 million-20.54Analyst Report
Increase in Short Interest
News Coverage
Gap Down
OLMA
Olema Pharmaceuticals
1.6$34.11+1.6%$1.35 billionN/A0.00Gap Up
Endo International logo
ENDP
Endo International
1.5$5.78+2.6%$1.30 billion$2.91 billion-8.50
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$34.44+6.6%$1.28 billionN/A-143.50Analyst Downgrade
News Coverage
Shattuck Labs logo
STTK
Shattuck Labs
1.5$29.50+0.0%$1.23 billionN/A0.00Analyst Report
Insider Selling
This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.